RxDoctor Payments Data

Lisa Ganjhu, DO

Gastroenterology · New York, NYNPI 1710970702

Payments from drug & device makers

$82,463in general payments, 2019–2025

Across 94 payments — averaging $877.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$64K
  • AbbVie$12K
  • Gilead$6K
  • QOL Medical, LLC$400
  • Mirum Pharmaceuticals, Inc.$150
  • Intercept Pharmaceuticals, Inc.$140
  • plus $121 from 1 others

What the payments were for

  • Consulting fees$5,2886%
  • Speaking & faculty fees$68,80383%
  • Travel & lodging$4,2835%
  • Food & beverage$4,0825%
  • Education$80%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,463 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$63,420
Medicare patients
152
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin35$110,138
LinzessLinaclotide64$34,679
MotegrityPrucalopride Succinate27$16,613
KristaloseLactulose12$7,187
Tenofovir Disoproxil Fumarate20$3,486
Ursodiol23$2,562
Omeprazole168$1,191
Esomeprazole Magnesium59$1,149
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl80$1,101
Lansoprazole87$1,021
Famotidine68$646
Pantoprazole Sodium76$591
Dicyclomine Hcl17$363
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl16$220
Metronidazole15$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$11,518$34,67964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →